Alfred Lloyd Bowie Jr. - 04 Feb 2026 Form 3 Insider Report for Eikon Therapeutics, Inc. (EIKN)

Role
Chief Financial Officer
Signature
/s/ Benjamin Thorner, Attorney-in-Fact
Issuer symbol
EIKN
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
3
Filing time
04 Feb 2026, 21:34:18 UTC
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bowie Alfred Lloyd Jr. Chief Financial Officer C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE /s/ Benjamin Thorner, Attorney-in-Fact 04 Feb 2026 0002104152

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EIKN Common Stock 51,572 04 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 55,698 $1.94 Direct F1
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 33,521 $9.85 Direct F2
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 26,147 $9.85 Direct F2
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 63,691 $9.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares underlying the option vest on the one year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each date.
F2 The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney